Connection

THOMAS COOPER to Humans

This is a "connection" page, showing publications THOMAS COOPER has written about Humans.
Connection Strength

0.624
  1. MBNL overexpression rescues cardiac phenotypes in a myotonic dystrophy type 1 heart mouse model. J Clin Invest. 2025 Feb 11; 135(7).
    View in: PubMed
    Score: 0.027
  2. Rescue of Scn5a mis-splicing does not improve the structural and functional heart defects of a DM1 heart mouse model. Hum Mol Genet. 2024 10 07; 33(20):1789-1799.
    View in: PubMed
    Score: 0.026
  3. Insights into Cell-Specific Functions of Microtubules in Skeletal Muscle Development and Homeostasis. Int J Mol Sci. 2023 Feb 02; 24(3).
    View in: PubMed
    Score: 0.023
  4. Clinical and Molecular Insights into Gastrointestinal Dysfunction in Myotonic Dystrophy Types 1 & 2. Int J Mol Sci. 2022 Nov 26; 23(23).
    View in: PubMed
    Score: 0.023
  5. Increased nuclear but not cytoplasmic activities of CELF1 protein leads to muscle wasting. Hum Mol Genet. 2020 06 27; 29(10):1729-1744.
    View in: PubMed
    Score: 0.019
  6. Endurance exercise leads to beneficial molecular and physiological effects in a mouse model of myotonic dystrophy type 1. Muscle Nerve. 2019 12; 60(6):779-789.
    View in: PubMed
    Score: 0.018
  7. Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1. Hum Mol Genet. 2018 08 15; 27(16):2789-2804.
    View in: PubMed
    Score: 0.017
  8. Protein sequestration as a normal function of long noncoding RNAs and a pathogenic mechanism of RNAs containing nucleotide repeat expansions. Hum Genet. 2017 09; 136(9):1247-1263.
    View in: PubMed
    Score: 0.016
  9. The roles of RNA processing in translating genotype to phenotype. Nat Rev Mol Cell Biol. 2017 02; 18(2):102-114.
    View in: PubMed
    Score: 0.015
  10. Neonatal cardiac dysfunction and transcriptome changes caused by the absence of Celf1. Sci Rep. 2016 10 19; 6:35550.
    View in: PubMed
    Score: 0.015
  11. Non-canonical RAN Translation of CGG Repeats Has Canonical Requirements. Mol Cell. 2016 04 21; 62(2):155-156.
    View in: PubMed
    Score: 0.014
  12. Roles for RNA-binding proteins in development and disease. Brain Res. 2016 09 15; 1647:1-8.
    View in: PubMed
    Score: 0.014
  13. Rbfox2-coordinated alternative splicing of Mef2d and Rock2 controls myoblast fusion during myogenesis. Mol Cell. 2014 Aug 21; 55(4):592-603.
    View in: PubMed
    Score: 0.013
  14. In Brief: (mis)splicing in disease. J Pathol. 2014 May; 233(1):1-3.
    View in: PubMed
    Score: 0.013
  15. The Mef2 transcription network is disrupted in myotonic dystrophy heart tissue, dramatically altering miRNA and mRNA expression. Cell Rep. 2014 Jan 30; 6(2):336-45.
    View in: PubMed
    Score: 0.012
  16. RNA-binding proteins in heart development. Adv Exp Med Biol. 2014; 825:389-429.
    View in: PubMed
    Score: 0.012
  17. Muscleblind-like 1 activates insulin receptor exon 11 inclusion by enhancing U2AF65 binding and splicing of the upstream intron. Nucleic Acids Res. 2014 Feb; 42(3):1893-903.
    View in: PubMed
    Score: 0.012
  18. Reexpression of pyruvate kinase M2 in type 1 myofibers correlates with altered glucose metabolism in myotonic dystrophy. Proc Natl Acad Sci U S A. 2013 Aug 13; 110(33):13570-5.
    View in: PubMed
    Score: 0.012
  19. Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy. Hum Gene Ther. 2013 May; 24(5):499-507.
    View in: PubMed
    Score: 0.012
  20. Pre-mRNA splicing in disease and therapeutics. Trends Mol Med. 2012 Aug; 18(8):472-82.
    View in: PubMed
    Score: 0.011
  21. RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity. Brain Res. 2012 Jun 26; 1462:100-11.
    View in: PubMed
    Score: 0.011
  22. Functional consequences of developmentally regulated alternative splicing. Nat Rev Genet. 2011 Sep 16; 12(10):715-29.
    View in: PubMed
    Score: 0.010
  23. Identification of MBNL1 and MBNL3 domains required for splicing activation and repression. Nucleic Acids Res. 2011 Apr; 39(7):2769-80.
    View in: PubMed
    Score: 0.010
  24. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Hum Mol Genet. 2010 Sep 15; 19(18):3614-22.
    View in: PubMed
    Score: 0.010
  25. Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum Mol Genet. 2010 Mar 15; 19(6):1066-75.
    View in: PubMed
    Score: 0.009
  26. The pathobiology of splicing. J Pathol. 2010 Jan; 220(2):152-63.
    View in: PubMed
    Score: 0.009
  27. Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans. 2009 Dec; 37(Pt 6):1281-6.
    View in: PubMed
    Score: 0.009
  28. PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest. 2009 Dec; 119(12):3797-806.
    View in: PubMed
    Score: 0.009
  29. Chemical reversal of the RNA gain of function in myotonic dystrophy. Proc Natl Acad Sci U S A. 2009 Nov 03; 106(44):18433-4.
    View in: PubMed
    Score: 0.009
  30. Molecular biology. Neutralizing toxic RNA. Science. 2009 Jul 17; 325(5938):272-3.
    View in: PubMed
    Score: 0.009
  31. CUGBP2 directly interacts with U2 17S snRNP components and promotes U2 snRNA binding to cardiac troponin T pre-mRNA. Nucleic Acids Res. 2009 Jul; 37(13):4275-86.
    View in: PubMed
    Score: 0.009
  32. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell. 2007 Oct 12; 28(1):68-78.
    View in: PubMed
    Score: 0.008
  33. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet. 2007 Oct; 8(10):749-61.
    View in: PubMed
    Score: 0.008
  34. Alternative splicing in disease. Adv Exp Med Biol. 2007; 623:212-23.
    View in: PubMed
    Score: 0.008
  35. A reversal of misfortune for myotonic dystrophy? N Engl J Med. 2006 Oct 26; 355(17):1825-7.
    View in: PubMed
    Score: 0.007
  36. Minigene reporter for identification and analysis of cis elements and trans factors affecting pre-mRNA splicing. Biotechniques. 2006 Aug; 41(2):177-81.
    View in: PubMed
    Score: 0.007
  37. Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy. Prog Mol Subcell Biol. 2006; 44:133-59.
    View in: PubMed
    Score: 0.007
  38. Use of minigene systems to dissect alternative splicing elements. Methods. 2005 Dec; 37(4):331-40.
    View in: PubMed
    Score: 0.007
  39. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. J Cell Sci. 2005 Jul 01; 118(Pt 13):2923-33.
    View in: PubMed
    Score: 0.007
  40. Identification of CELF splicing activation and repression domains in vivo. Nucleic Acids Res. 2005; 33(9):2769-80.
    View in: PubMed
    Score: 0.007
  41. Identification of putative new splicing targets for ETR-3 using sequences identified by systematic evolution of ligands by exponential enrichment. Mol Cell Biol. 2005 Feb; 25(3):879-87.
    View in: PubMed
    Score: 0.007
  42. Alternative splicing regulation impacts heart development. Cell. 2005 Jan 14; 120(1):1-2.
    View in: PubMed
    Score: 0.007
  43. Muscleblind proteins regulate alternative splicing. EMBO J. 2004 Aug 04; 23(15):3103-12.
    View in: PubMed
    Score: 0.006
  44. ETR-3 and CELF4 protein domains required for RNA binding and splicing activity in vivo. Nucleic Acids Res. 2004; 32(3):1232-41.
    View in: PubMed
    Score: 0.006
  45. CELF6, a member of the CELF family of RNA-binding proteins, regulates muscle-specific splicing enhancer-dependent alternative splicing. J Biol Chem. 2004 Apr 23; 279(17):17756-64.
    View in: PubMed
    Score: 0.006
  46. Finding signals that regulate alternative splicing in the post-genomic era. Genome Biol. 2002 Oct 23; 3(11):reviews0008.
    View in: PubMed
    Score: 0.006
  47. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell. 2002 Jul; 10(1):45-53.
    View in: PubMed
    Score: 0.006
  48. Dynamic antagonism between ETR-3 and PTB regulates cell type-specific alternative splicing. Mol Cell. 2002 Mar; 9(3):649-58.
    View in: PubMed
    Score: 0.005
  49. Highlights of alternative splicing regulation session: yes, no, maybe--a history of paradigm shifts. Sci STKE. 2001 Oct 23; 2001(105):pe35.
    View in: PubMed
    Score: 0.005
  50. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet. 2001 Sep; 29(1):40-7.
    View in: PubMed
    Score: 0.005
  51. The CELF family of RNA binding proteins is implicated in cell-specific and developmentally regulated alternative splicing. Mol Cell Biol. 2001 Feb; 21(4):1285-96.
    View in: PubMed
    Score: 0.005
  52. Binding of PurH to a muscle-specific splicing enhancer functionally correlates with exon inclusion in vivo. J Biol Chem. 2000 Jul 07; 275(27):20618-26.
    View in: PubMed
    Score: 0.005
  53. RNA processing and human disease. Cell Mol Life Sci. 2000 Feb; 57(2):235-49.
    View in: PubMed
    Score: 0.005
  54. Alu insertion variants alter mRNA splicing. Nucleic Acids Res. 2019 01 10; 47(1):421-431.
    View in: PubMed
    Score: 0.004
  55. Muscle-specific splicing of a heterologous exon mediated by a single muscle-specific splicing enhancer from the cardiac troponin T gene. Mol Cell Biol. 1998 Aug; 18(8):4519-25.
    View in: PubMed
    Score: 0.004
  56. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science. 1998 May 01; 280(5364):737-41.
    View in: PubMed
    Score: 0.004
  57. The regulation of splice-site selection, and its role in human disease. Am J Hum Genet. 1997 Aug; 61(2):259-66.
    View in: PubMed
    Score: 0.004
  58. Identification of a new class of exonic splicing enhancers by in vivo selection. Mol Cell Biol. 1997 Apr; 17(4):2143-50.
    View in: PubMed
    Score: 0.004
  59. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature. 2015 Sep 17; 525(7569):384-8.
    View in: PubMed
    Score: 0.003
  60. A subset of SR proteins activates splicing of the cardiac troponin T alternative exon by direct interactions with an exonic enhancer. Mol Cell Biol. 1995 Sep; 15(9):4898-907.
    View in: PubMed
    Score: 0.003
  61. Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins. Genome Res. 2015 Jun; 25(6):858-71.
    View in: PubMed
    Score: 0.003
  62. Pumilio1 haploinsufficiency leads to SCA1-like neurodegeneration by increasing wild-type Ataxin1 levels. Cell. 2015 Mar 12; 160(6):1087-98.
    View in: PubMed
    Score: 0.003
  63. Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3'-UTR landscape across seven tumour types. Nat Commun. 2014 Nov 20; 5:5274.
    View in: PubMed
    Score: 0.003
  64. The cardiac troponin T alternative exon contains a novel purine-rich positive splicing element. Mol Cell Biol. 1993 Jun; 13(6):3660-74.
    View in: PubMed
    Score: 0.003
  65. In vitro splicing of cardiac troponin T precursors. Exon mutations disrupt splicing of the upstream intron. J Biol Chem. 1992 Mar 15; 267(8):5330-8.
    View in: PubMed
    Score: 0.003
  66. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci U S A. 2011 Mar 01; 108(9):3665-70.
    View in: PubMed
    Score: 0.003
  67. Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: two individual consequences of CUG trinucleotide repeats. Exp Neurol. 2008 Apr; 210(2):467-78.
    View in: PubMed
    Score: 0.002
  68. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1. Hum Mol Genet. 2006 Jul 01; 15(13):2138-45.
    View in: PubMed
    Score: 0.002
  69. Insulin receptor splicing alteration in myotonic dystrophy type 2. Am J Hum Genet. 2004 Jun; 74(6):1309-13.
    View in: PubMed
    Score: 0.002
  70. Myotonic dystrophy: discussion of molecular basis. Adv Exp Med Biol. 2002; 516:27-45.
    View in: PubMed
    Score: 0.001
  71. Alternative splicing determines the intracellular localization of the novel nuclear protein Nop30 and its interaction with the splicing factor SRp30c. J Biol Chem. 1999 Apr 16; 274(16):10951-62.
    View in: PubMed
    Score: 0.001
  72. A short sequence within two purine-rich enhancers determines 5' splice site specificity. Mol Cell Biol. 1998 Jan; 18(1):343-52.
    View in: PubMed
    Score: 0.001
  73. A 32-nucleotide exon-splicing enhancer regulates usage of competing 5' splice sites in a differential internal exon. Mol Cell Biol. 1995 Aug; 15(8):3979-88.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.